A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

@article{Gopal2011A5O,
  title={A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.},
  author={Srihari Gopal and Ujjwala Vijapurkar and Pilar Lim and Margarita Morozova and Mari{\"e}lle Eerdekens and David Hough},
  journal={Journal of psychopharmacology},
  year={2011},
  volume={25 5},
  pages={685-97}
}
The safety and tolerability of paliperidone palmitate, an injectable atypical antipsychotic agent, were assessed in a 1-year open-label extension of a double-blind study in patients with schizophrenia. Patients from the double-blind study who experienced a recurrence, remained recurrence free until study end, or who were in the transition, maintenance or double-blind phases and had received at least one injection of paliperidone palmitate when enrollment was stopped, were eligible for the open… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…